These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36720562)

  • 21. Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011-2014.
    Schuh T; Reichardt B; Finsterer J; Stöllberger C
    J Thromb Thrombolysis; 2016 Oct; 42(3):447-51. PubMed ID: 27221106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationships, Current Issues, Safety and Efficacy of Oral Anticoagulation in Cancer Patients with Atrial Fibrillation.
    Franchina AG; Rocchetti M; Sala E; Laricchia A; Minardi A; Spangaro A; Guazzi M; Lucreziotti S; Cereda A
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
    See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in anticoagulant prescribing: a review of local policies in English primary care.
    Ho KH; van Hove M; Leng G
    BMC Health Serv Res; 2020 Apr; 20(1):279. PubMed ID: 32245380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
    Yoshihisa A; Sato Y; Sato T; Suzuki S; Oikawa M; Takeishi Y
    BMC Cardiovasc Disord; 2018 Jan; 18(1):11. PubMed ID: 29368593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR.
    Kawashima H; Watanabe Y; Hioki H; Kozuma K; Kataoka A; Nakashima M; Nagura F; Nara Y; Yashima F; Tada N; Naganuma T; Yamawaki M; Yamanaka F; Shirai S; Mizutani K; Tabata M; Ueno H; Takagi K; Yamamoto M; Hayashida K;
    JACC Cardiovasc Interv; 2020 Nov; 13(22):2587-2597. PubMed ID: 33129818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association between increasing oral anticoagulant prescribing and atrial fibrillation related stroke in Ireland.
    Kennedy C; Gabr A; McCormack J; Collins R; Barry M; Harbison J
    Br J Clin Pharmacol; 2022 Jan; 88(1):178-186. PubMed ID: 34131941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
    Simonyi G; Ferenci T; Finta E; Gasparics R; Medvegy M
    Orv Hetil; 2019 Mar; 160(13):509-515. PubMed ID: 30907102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data.
    Warkentin L; Hueber S; Deiters B; Klohn F; Kühlein T
    Thromb J; 2022 May; 20(1):31. PubMed ID: 35619140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
    Trujillo TC; Dobesh PP; Crossley GH; Finks SW
    Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.
    Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z
    Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis.
    Li D; Chang P; Zhang H; Bai F; Wu Q
    Eur J Clin Pharmacol; 2023 Apr; 79(4):461-471. PubMed ID: 36795127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulant treatment in elderly patients with atrial fibrillation: a position paper.
    Hanon O; Jeandel C; Jouanny P; Paccalin M; Puisieux F; Krolak-Salmon P; Berrut G
    Geriatr Psychol Neuropsychiatr Vieil; 2019 Dec; 17(4):341-354. PubMed ID: 32912842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis.
    Rujirachun P; Charoenngam N; Wattanachayakul P; Winijkul A; Owattanapanich W; Ungprasert P
    Acta Cardiol; 2020 Dec; 75(8):724-731. PubMed ID: 31558097
    [No Abstract]   [Full Text] [Related]  

  • 37. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reimbursement and use of oral anticoagulants during 2014-2022 - A register-based study.
    Aarnio E; Huupponen R; Martikainen J; Korhonen MJ
    Explor Res Clin Soc Pharm; 2023 Sep; 11():100284. PubMed ID: 37538990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation.
    Rivera-Caravaca JM; Marín F; Esteve-Pastor MA; Gálvez J; Lip GYH; Vicente V; Roldán V
    BMJ Open; 2019 Dec; 9(12):e033712. PubMed ID: 31843852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.
    Potpara TS; Dagres N; Mujović N; Vasić D; Ašanin M; Nedeljkovic M; Marin F; Fauchier L; Blomstrom-Lundqvist C; Lip GY
    Adv Ther; 2017 Feb; 34(2):357-377. PubMed ID: 27933569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.